Docetaxel in neoadjurant therapy of early-stage non-small cell lung cancer;Docetaxel für die neoadjuvanten therapieansätze der frühen stadien des nicht-kleinzelligen bronchuskarzinoms

Onkologie

Volumn 26, Issue SUPPL. 7, 2003, Pages 33-36

  Betticher, D C ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Chemotherapy: neoadjuvant, preoperative; Docetaxel; Lymph nodes: mediastinal; Non small cell lung cancer (NSCLC)

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOSTATIC AGENT; DOCETAXEL; ERYTHROPOIETIN; MITOMYCIN C; NAVELBINE; VINBLASTINE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; MEDIASTINUM LYMPH NODE; META ANALYSIS; MORBIDITY; QUALITY OF LIFE; REVIEW; SURGICAL MORTALITY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM STAGING; SURVIVAL RATE; TAXOIDS;

EID: 0348231916     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076172     Document Type: Review

References (13)

1. Albain KS, Pass HI: Induction therapy for locally advanced non-small-cell lung cancer; in Lung Cancer: Principles and Practice, ed 2. Philadelphia, USA, Lippincott Williams and Wilkins, 2000, pp 798-820.
2. Le Chevalier T, for the IALT Investigators: Results of the randomised international adjuvant lung cancer trial (IALT): Cisplatin-based chemotherapy (CT) vs. no CT in 1867 patients with resected non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003;22:abstr 6.
3. Depierre A, Westeel V, Jacoulet P: Preoperative chemotherapy for non-small-cell lung cancer. Cancer Treat Rev 2001;27:119-127.
4. Wagner H Jr, Lad T, Piantadosi S, Ruckdeschel JC: Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small-cell cancer of the lung. LCSG 881. Chest 1994;106(suppl 6):348S-354S.
5. Fossella F, Pereira JR, Von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczȩsna A, Fidias P, Millward M, Belani CP: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 Study Group. J Clin Oncol 2003;21:3016-3024.
6. Mattson KV, Abratt RP, Velde G, Krofta K: Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: A multinational randomized phase III study. Ann Oncol 2003;14:116-122.
7. Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Roth A, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wehrnli M, Cerny T, Ris H: Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small cell lung cancer: A multicenter phase II trial21. J Clin Oncol 2003a;21:1752-1759.
8. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, Braun D, Breton JL, Lemarie E, Gouva S, Paillot N, Brechot JM, Janicot H, Lebas FX, Terrioux P, Clavier J, Foucher P, Monchatre M, Coetmeur D, Level MC, Leclerc P, Blanchon F, Rodier JM, Thiberville L, Villeneuve A, Westeel V, Chastang C: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-253.
9. Betticher DC, Ratschiller D, Gugger M, Borner M, Lasek A, Rickert P, Smith SL, Knapp T, Santibanez-Koref MF, Heighway J: Dual-channel tumor/normal expression profiles of resected, chemoptherapy-treated, non-small-cell lung cancers (NSCLC) compared to not-treated NSCLC pairs show patterns closer to normal lung tissue than the untreated tumours. Lung Cancer 2003b;41 (suppl 2): 16 (WCLC Vancouver).
10. Pless M, Stahel R, Balmer-Majno S, Stupp R, Betticher DC, Egli F, Rufibach K, Thierstein S, Ris HB, Mirimanoff RO: Neoadjuvant chemo- and radiotherapy in stage IIIA (N2) non-small cell lung cancer (NSCLC). Rationale for a randomized trial by the Swiss Group for Clinical Cancer Research (SAKK). Lung Cancer 2003;41 (suppl 2):241 (WCLC Vancouver).
11. Stupp R, Stahel RA, Kann R, Betticher DC, Zouhair A, Jost L, Rufibach K, Thierstein S, Ris HB, Pless M: Neoadjuvant chemo- and radiotherapy for stage IIIB non-small cell lung cancer (NSCLC). A prospective multicenter trial by the Swiss Group for Clinical Cancer Research (SAKK). Lung Cancer 2003;41(suppl 2):245 (WCLC Vancouver).
12. Griesinger F, Glätzner T, Schmidberger H, Andreas S, Schirren J, Dörge H, Herse B, Leupold H, Hemmerlein B, Baum RP: FDG-PET response predicts overall and disease free survival after induction chemotherapy with docetaxel (D) plus carboplatin (C) and erythropoietin (EPO) in locally advanced (stage III) non-small cell lung cancer (NSCLC). Lung Cancer 2003;41 (suppl 2):156 (WCLC Vancouver).
13. Nishimura T, Ikeda A, Katakami N, Okazaki M, Nishio C, Fujita S, Hasegawa T, Nishiuchi S, Umeda B: Phase II study of induction carboplatin (CAR) and docetaxel (DOC) with concurrent thoracic radiation (CTRT) followed by surgical resection in stage IB, IIA and IIB non-small-cell-lung-cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:abstr 2767.